We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Verapamil (Calan / Isoptin) — non-dihydropyridine calcium-channel blocker
A decades-old non-dihydropyridine calcium-channel blocker for hypertension, angina, and arrhythmia, being repurposed to PRESERVE pancreatic beta-cell function in new-onset type-1 diabetes. Two randomized trials (adults — Nature Medicine 2018; children/adolescents — JAMA 2023, CLVer) show it partially preserves C-peptide. The benefit is partial and adjunctive — not a cure, and it wanes after stopping. A prescription drug, not a supplement.
Prescription medication — not a dietary supplement
Verapamil is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Verapamil studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1975–2026 with a typical study size of 1,434 participants.
Based on 643 studies · 20 meta-analyses · 614 RCTs · 3,545 total participants
Confidence
High confidenceBy outcome
Verapamil has two randomized, double-blind, placebo-controlled trials (adults — Nature Medicine 2018; children/adolescents — JAMA 2023) showing it partially preserves stimulated C-peptide in new-onset type-1 diabetes, grounded in a clear TXNIP/beta-cell mechanism and backed by decades of approved cardiovascular use — but the beta-cell benefit is partial, adjunctive, non-curative, appears to wane after stopping, and durability is unresolved, so the repurposing use stays emerging.
649 rigorous studies
623 randomized trials · 22 meta-analyses · 4 systematic reviews
Our evidence rating for Verapamil is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
24 trials ongoing or recruiting · 108 completed on ClinicalTrials.gov
22 of the completed trials have posted results
Registered trials show research momentum for Verapamil, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Verapamil is a non-dihydropyridine calcium-channel blocker approved for decades to treat hypertension, angina, and supraventricular arrhythmias by slowing AV-node conduction and relaxing vascular smooth muscle.
Its novel, evidence-backed repurposing is in type-1 diabetes: preclinical work showed that verapamil lowers expression of thioredoxin-interacting protein (TXNIP) in pancreatic beta cells — a protein that drives beta-cell apoptosis under glucotoxic stress — and that this promotes beta-cell survival.
That mechanism was translated to humans in two randomized, double-blind, placebo-controlled trials.
The Ver-A-T1D trial (Ovalle/Shalev, Nature Medicine 2018) found that once-daily oral verapamil added to insulin for 12 months in adults with recent-onset T1D improved mixed-meal-stimulated C-peptide (a measure of endogenous insulin/beta-cell function), reduced the rise in insulin requirements, and lowered hypoglycemic events.
The CLVer trial (Forlenza/Moran, JAMA 2023) replicated this in children and adolescents aged 7–17 with newly diagnosed T1D: verapamil partially preserved stimulated C-peptide at 52 weeks (about 30% higher than placebo).
The honest framing is that this is adjunctive, partial beta-cell preservation — verapamil does not cure T1D, does not eliminate insulin dependence, and the C-peptide benefit appears to wane after the drug is stopped; longer-term durability and optimal treatment length are unresolved.
As a cardiovascular drug verapamil is well characterized and generally well tolerated, but it carries real cardiac and GI trade-offs: bradycardia, AV block, hypotension, and constipation, plus contraindications in significant heart-failure or conduction disease.
Verapamil is a prescription drug used off-label for beta-cell preservation in T1D, ideally within or alongside a clinical-trial framework.
The score reflects genuinely randomized human evidence for a novel beta-cell-preserving effect plus decades of approved cardiovascular use, set against a benefit that is partial, adjunctive, non-curative, and not yet shown to be durable.
Verapamil decreases expression of thioredoxin-interacting protein (TXNIP), a driver of glucotoxicity-induced beta-cell apoptosis — promoting survival of insulin-producing beta cells.
Blocking L-type calcium channels lowers intracellular calcium overload (the upstream trigger for TXNIP induction) and underlies the approved cardiovascular effects on vascular tone and AV-node conduction.
Slowed AV-node conduction and vascular smooth-muscle relaxation deliver the established antiarrhythmic, antianginal, and antihypertensive actions — and the bradycardia/AV-block trade-off.
How Verapamil works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Beta-cell preservation is adjunctive to insulin, not a replacement — discuss with an endocrinologist, ideally within a trial framework.
Contraindicated or high-risk — verapamil depresses contractility and AV conduction.
High interaction risk — combined cardiac suppression or digoxin toxicity; close monitoring required.
Additive AV-node suppression — risk of severe bradycardia, heart block, and hypotension.
Verapamil raises digoxin levels — monitor for digoxin toxicity.
Verapamil inhibits CYP3A4, raising levels of some statins (myopathy risk) and other substrates; avoid grapefruit juice.
Tip: Most common side effect; maintain fluid/fiber intake; dose adjustment if persistent.
Tip: Monitor heart rate and blood pressure; caution with beta-blockers and in conduction disease.
Tip: Avoid in pre-existing high-grade AV block without a pacemaker; ECG monitoring during titration.
Verapamil has an evidence score of 4.6/10 — emerging evidence based on 55 indexed studies, including 1 meta-analysis. A decades-old non-dihydropyridine calcium-channel blocker for hypertension, angina, and arrhythmia, being repurposed to PRESERVE pancreatic beta-cell function in new-onset type-1 diabetes. Two randomized trials (adults — Nature Medicine 2018; children/adolescents — JAMA 2023, CLVer) show it partially preserves C-peptide. The benefit is partial and adjunctive — not a cure, and it wanes after stopping. A prescription drug, not a supplement. Representative study: PMID 40111679.
The commonly studied dose of Verapamil is Off-label beta-cell use in new-onset T1D mirrors trial dosing (the adult Ver-A-T1D trial used roughly weight-based ~120–360 mg/day of extended-release verapamil) added to a standard insulin regimen, under a clinician — ideally within a trial framework. A prescription drug; not an approved or standardized regimen for T1D.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Verapamil is with meals. Take it with food. Extended-release verapamil is taken with food, commonly once daily; titrate to limit bradycardia/hypotension and constipation.
Verapamil should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are constipation, bradycardia / hypotension / dizziness, AV block. Use caution if any of these apply to you: Significant left-ventricular dysfunction / decompensated heart failure; Severe bradycardia, sick-sinus syndrome, or second/third-degree AV block (without a pacemaker); Severe hypotension or cardiogenic shock.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Canagliflozin
Mostly mechanism / observationalAn SGLT2-inhibitor diabetes drug (Invokana) that lowers glucose by excreting it in urine. It extended lifespan in male mice in the NIA aging program, and the SGLT2 class has strong proven cardiovascular, kidney, and heart-failure benefits in humans. Longevity benefit itself is unproven; carries genital-infection and (rarely) ketoacidosis risks. Prescription drug, not a supplement.
Empagliflozin
Mostly mechanism / observationalAn SGLT2-inhibitor diabetes drug (Jardiance) with the strongest human outcome evidence of its class — it cuts cardiovascular death, heart-failure hospitalization, and kidney-disease progression even in non-diabetics. The most widely used SGLT2 for off-label 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement.
Dapagliflozin
Mostly mechanism / observationalAn SGLT2-inhibitor diabetes drug (Farxiga/Forxiga) with broad, robust human outcome evidence — it cuts heart-failure hospitalization and cardiovascular death across the ejection-fraction spectrum and slows kidney-disease progression, including in non-diabetics. The sibling of empagliflozin, used off-label for 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 643 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research